Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Lung Neoplasms 2Neoplasms 1Neoplasm Metastasis 1Metastatic Pancreatic Adenocarcinoma 1Mesothelioma 1Breast Neoplasms 1

Interventions

LMB-100 4Cyclophosphamide 3fludarabine 2Plicamycin 2Cisplatin 2talazoparib 1pembrolizumab 1olaparib 1fludarabine phosphate 1decitabine and cedazuridine drug combination 1amatuximab 1alvocidib 1aldesleukin 1Surgical Procedures, Operative 1Pentostatin 1Pemetrexed 1Paclitaxel 1Magnetic Resonance Imaging 1Ipilimumab 1Fluorouracil 1Fluorodeoxyglucose F18 1Famotidine 1FANG vaccine 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Dexamethasone 1Depsipeptides 1Cytoreduction Surgical Procedures 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Mesothelioma × 130-nm albumin-bound paclitaxel × Clear all
NCT02798536 2022-08-23

Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
21 enrolled 19 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡